Cannabis / CBD
When the federal government finally nudged cannabis from the forbidden list to Schedule III in 2024, the headline was clear: a new regulatory chapter for growers and retailers. For investors, however, the real story lies in how that shift ripples through the balance sheets of cannabis real-estate investment trusts (REITs)
Cannabis / CBD
Picture this: a mid-cap cannabis company suddenly sheds the heavy regulatory ballast that has been dragging its cost of capital down like an anchor. In 2024, lawmakers are buzzing about a Schedule I-to-III reclassification, and the financial ripple effects could be as dramatic as a 30% discount-rate haircut. If you’
Cannabis / CBD
When a courtroom decision suddenly lifts a weight off a small business’s shoulders, the relief can be palpable - especially for dispensaries that have been watching the clock tick on looming fines. The March 15, 2024 ruling from the Michigan Court of Appeals did just that for Upper Michigan’
Cannabis / CBD
Why Seniors Are Turning to CBD for Joint Pain When the aches of arthritis start to dictate daily routines, many older adults are swapping pills for a plant-based alternative that won’t leave them drowsy or dependent. CBD offers a non-opioid option that eases arthritis discomfort while fitting seamlessly into
Cannabis / CBD
Imagine a researcher walking into a lab in 2025, laptop in hand, only to discover that the federal grant portal now lists cannabis alongside antibiotics and vaccines. That shift from “no medical use” to “eligible for funding” could happen sooner than most expect, thanks to a proposal from the Trump
Cannabis / CBD
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. The Current Schedule I Barrier: How Federal Classification Stifles Pediatric Research Because cannabis remains a Schedule I drug, any researcher who wants to study it
Cannabis / CBD
Imagine reaching for a gummy that promises calm without the headache of a surprise drug test. In 2024, more consumers are turning to CBD edibles, but the market remains a minefield of mislabeled products and hidden contaminants. Why Lab Testing Is the First Line of Defense Lab testing separates trustworthy
Cannabis / CBD
When the Texas Senate voted to move cannabis from Schedule I to Schedule II in March 2024, the decision rippled far beyond the headlines. For scientists chasing cures for ultra-rare conditions, the change feels like a new highway opening after years of detours. Below, we walk through the practical steps
Cannabis / CBD
When a police raid nets a truckload of high-THC flower, the headline number - $1.3 million - can feel like a jackpot. Yet for a city juggling a $1.8 billion budget, that windfall is less a lottery win and more a puzzle piece that could reshape spending priorities.